DelveInsight's 'Non-muscle Invasive Bladder Cancer (NMIBC)-Epidemiology Forecast-2030' report delivers an in-depth understanding of the disease, historical and forecasted NMIBC epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Non-muscle Invasive Bladder Cancer (NMIBC) Understanding
Non-muscle invasive bladder cancer (NMIBC) is cancer found in the tissue that lines the inner surface of the bladder. The bladder muscle is not involved.
NMIBC, formerly known as superficial bladder cancer, is a common, heterogeneous disease associated with high rates of recurrence and that often requires lifelong surveillance.
The bladder is a vessel that stores urine produced by the kidneys before excretion. The bladder itself is made up of several tissue layers. The first two layers include the urothelial and the lamina propria layers. The urothelial or mucosal layer makes contact with the bladder contents, while the lamina propria, or submucosal layer, and connects the urothelial layer to the underlying smooth muscle. Bladder cancer is a common malignancy arising from the urothelial cells and is responsible for considerable morbidity and mortality. The most common symptom of bladder cancer is hematuria, which occurs in 80-90% of patients. Approximately 70% of newly diagnosed cases of bladder cancer are NMIBC, meaning that they are confined to the urothelial and lamina propria layers of the bladder. Among NMIBCs, around 70% present as Ta lesions (papillary tumor confined to the urothelium), 20% as T1 lesions (tumor invades the lamina propria), and 10% as carcinoma in situ (CIS) (flat, high-grade tumor confined to the urothelial layer).
Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent cases of Bladder Cancer, Diagnosed Prevalent cases of Bladder cancer, Diagnosed Prevalent cases of NMIBC, Age-specific Diagnosed Prevalence of NMIBC, Tumor (T) stage-specific Diagnosed Prevalence of NMIBC, Grade-specific Diagnosed Prevalence of NMIBC, and Risk-specific Diagnosed Prevalence of NMIBC a scenario of NMIBC in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.
NMIBC Detailed Epidemiology Segmentation
- In the 7MM, the total diagnosed prevalent population of NMIBC was estimated to be 533,263 cases in 2017, which is expected to increase in the forecast period
- The United States accounted for the maximum diagnosed prevalent population among the 7MM in 2017.
- In EU5 countries, Germany accounted for the highest diagnosed cases of NMIBC while United Kingdom had the lowest diagnosed prevalent population in 2017.
- In the United States, there were 6,841, 58,791, 125,919 and 22,234 cases for >44, 45-64, 65--84 and >85 years, in 2017 which is expected to rise in the forecast period.
- There are different stages in which NMIBC is classified which include Ta (lowest stage), Stage Tis and Stage T1. Over half of patients with low-grade Ta cancers will have a tumor recurrence. In 2017, the diagnosed prevalent population of stage Ta, low grade NMIBC was 134,684 and stage Ta, high grade NMIBC was 14,965 in the United States.
- In 2017, the diagnosed prevalent population of high risk NMIBC was 26,366 and low risk NMIBC was 48,325 in Japan.
Scope of the Report:
- The report covers the descriptive overview of NMIBC, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
- The report assesses the disease risk and burden and highlights the unmet needs of NMIBC.
- The report provides the segmentation of the disease epidemiology for 7MMby Total Prevalent Cases of NMIBC, Total Diagnosed and Treated Cases of NMIBC.
- Eleven-Year Forecast of NMIBC
- 7MM Coverage
- Prevalent cases of Bladder Cancer
- Diagnosed Prevalent cases of Bladder cancer
- Diagnosed Prevalent cases of NMIBC
- Age-specific Diagnosed Prevalence of NMIBC
- Tumor (T) stage-specific Diagnosed Prevalence of NMIBC
- Grade-specific Diagnosed Prevalence of NMIBC, and
- Risk-specific Diagnosed Prevalence of NMIBC
Key Questions Answered
- What is the disease risk, burden and unmet needs of NMIBC?
- What is the historical NMIBC patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
- What would be the forecasted patient pool of NMIBC at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to NMIBC?
- Out of the countries mentioned above, which country would have the highest prevalent population of NMIBC during the forecast period (2020-2030)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?
Reasons to buy:
The NMIBC report will allow the user to -
- Develop business strategies by understanding the trends shaping and driving the 7MM NMIBC market.
- Quantify patient populations in the 7MM NMIBC market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the specific type of NMIBC that presents the best opportunities for NMIBC therapeutics in each of the markets covered.
- The NMIBC epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
- The NMIBC epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Study Period: 2017-2030